Inhibitors of SARS-Coronavirus-2 infection
Akronym
iCoin
Bidragets beskrivning
Pharmaceutical interventions to decrease COVID-19 severity and lethality are urgently needed globally. Our multidisciplinary consortium is focused to develop therapies for COVID-19 at University of Helsinki and VTT using different approaches: by cloning and producing human antibodies cloned from individual immune cells from the patients recovered from COVID-19 disease, and by screening safe-in-human compounds for SARS-CoV-2 inhibitory effects in in vitro systems. Structural studies will produce information of SARS-CoV-2 binding at the molecular level, informing also further engineering of the binding antibodies. Animal models of SARS-CoV-2 infection will be developed for further in vivo testing of the inhibitors.
Visa merStartår
2020
Slutår
2022
Beviljade finansiering
Rollen i Finlands Akademis konsortium
Ledare
Finansiär
Finlands Akademi
Typ av finansiering
Akademiprojekt med särskild inriktning
Övriga uppgifter
Finansieringsbeslutets nummer
336490
Vetenskapsområden
Växtbiologi, mikrobiologi, virologi
Forskningsområden
Mikrobiologia
Temaområden
Lisätalousarvio III 2020
Identifierade teman
covid, pandemic, vaccines